Disease Control and Manageable Toxicity With Epcoritamab in Refractory Diffuse Large B‐Cell Lymphoma‐Type Richter Syndrome: A Case Report in an Elderly Patient
Cancer Reports · 2025
DOI: 10.1002/cnr2.70349 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cancer Reports, 2025. Verfasst von Takumi Nishikawa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oita Prefectural Hospital, Oita, Japan. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antibodies, Bispecific, Leukemia, Lymphocytic, Chronic, B-Cell, Antineoplastic Agents, Immunological. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Richter syndrome (RS) is an aggressive transformation of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with poor prognosis. No standard treatment for RS has been established. Epcoritamab, a CD3xCD20 bispecific antibody, may offer clinical benefit. Case An 80‐year‐old woman was diagnosed with SLL in 2017 and remained untreated for nearly 6 years. In 2023, she developed a bulky abdominal tumor. Although the initial biopsy showed SLL progression without transformation, subsequent treatments with acalabrutinib, venetoclax plus rituximab, and bendamustine plus rituximab failed. In 2024, transformation to diffuse large B‐cell lymphoma‐type RS (DLBCL‐RS) was confirmed. Two lines of cytotoxic regimens were ineffective, with rapid tumor growth. Epcoritamab was initiated as third‐line therapy. Grade 1–3 cytokine release syndrome occurred but resolved with standard management. No neurotoxicity was observed. Partial response (PR) was achieved by week 12, and the patient has maintained PR for 10 months. Infections including COVID‐19 and cytomegalovirus were managed successfully, and immunoglobulin replacement was introduced for hypogammaglobulinemia.
Conclusion
This case highlights the potential of epcoritamab as an important treatment option for elderly patients with refractory DLBCL‐RS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Oita Prefectural Hospital, Oita, Japan.
- Department of Pathology, Oita Prefectural Hospital, Oita, Japan.
ORCID-Profile: Takumi Nishikawa, Masuho Saburi, Shogo Urabe, Eiichi Ohtsuka
Zitieren
APA
Nishikawa, T., Saburi, M., Urabe, S., & Ohtsuka, E. (2025). Disease Control and Manageable Toxicity With Epcoritamab in Refractory Diffuse Large B‐Cell Lymphoma‐Type Richter Syndrome: A Case Report in an Elderly Patient. Cancer Reports. https://doi.org/10.1002/cnr2.70349
Vancouver
Nishikawa T, Saburi M, Urabe S, Ohtsuka E. Disease Control and Manageable Toxicity With Epcoritamab in Refractory Diffuse Large B‐Cell Lymphoma‐Type Richter Syndrome: A Case Report in an Elderly Patient. Cancer Reports. 2025. doi:10.1002/cnr2.70349
BibTeX
@article{Nishikawa2025,
author = {Nishikawa, Takumi and Saburi, Masuho and Urabe, Shogo and Ohtsuka, Eiichi},
title = {Disease Control and Manageable Toxicity With Epcoritamab in Refractory Diffuse Large B‐Cell Lymphoma‐Type Richter Syndrome: A Case Report in an Elderly Patient},
journal = {Cancer Reports},
year = {2025},
doi = {10.1002/cnr2.70349}
}
EUVIMED